Deciphex
Glasnevin
About Deciphex
Founded in 2017, Deciphex aims to transform diagnostic workflows through AI-powered digital pathology to improve patient outcomes worldwide. Its two flagship platforms target distinct markets: Diagnexia connects global subspecialty pathologists for rapid diagnostics and backlog reduction, while Patholytix accelerates drug development through optimized preclinical safety assessments. By automating routine tasks, these platforms enable pathologists to focus on complex cases while delivering faster, more reliable diagnoses. Through this combination of AI innovation and clinical expertise, Deciphex is advancing both healthcare delivery and therapeutic development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $84.7M
- Funding stage: Late Stage Venture
- Last round: Debt Financing (Oct 2025)
- Website: deciphex.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Health Diagnostics, Software
Social Profiles
Canonical: https://fsome.com/organization/deciphex-5692 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.